The present invention relates to a synthetic prosthesis for tissue reinforcement, the prosthesis comprising a porous knit and a biodegradable adhesion barrier film provided on one face of said knit. The prosthesis of the invention is particularly intended for the reinforcement of soft tissue where a weakness exists such as the primary abdominal wall and incisional hernias.
Reinforcement prostheses, for example prostheses for reinforcing the abdominal wall, are widely used in the surgical field. These prostheses are intended to treat hernias by temporarily or permanently filling a tissue defect. These prostheses are generally made of biocompatible prosthetic fabric, for example knits, and can have a number of shapes, for example rectangular, circular or oval, depending on the anatomical structure to which they are to be fitted.
Prosthetic fabrics such as knits are intrinsically adhesiogenic and fibrogenic, irrespective of the nature of the tissues with which they are put in contact. It is desirable to provide reinforcement prostheses that, although based on prosthetic fabric, also prevent post-surgical adhesions, especially when they are positioned intraperitoneally.
Postsurgical adhesions include all non-anatomical fibrous connections accidentally induced by a surgical act during the normal process of cicatrization. They may occur in all surgical disciplines regardless of the operation in question. Postsurgical adhesions can provoke syndromes which can be classed principally as chronic pain, occlusive syndromes and female infertility. Furthermore, they increase very substantially the risks of making errors in follow-up surgery, while prolonging the operating times, since the preliminary dissection can be very awkward in such cases.
To remedy this problem, it was suggested to render one face of these reinforcement prostheses completely smooth during the initial inflammatory phase, and therefore not favorable to the generation of adhesions. To do this, a physical barrier is interposed between the structures which are not intended to adhere to each other.
However, the desired barrier effect poses the problem of the intrinsic adhesive power of this barrier. The reason is that if the barrier is made of a non biodegradable material, it can itself be the source of adhesions over the course of time; and if it is biodegradable, its biodegradation must be sufficiently noninflammatory so as not to cause adhesions itself on one hand, and on the other hand, its biodegradation kinetics should be appropriate so as to allow the barrier to remain integrate during the time needed for it to perform its function of prevention of formation of adhesions.
In the present application, the term “biodegradable” is defined to include both bioabsorbable and bioresorbable materials. By biodegradable, it is meant that the materials decompose, or lose structural integrity under body conditions (e.g., enzymatic degradation or hydrolysis) or are broken down (physically or chemically) under physiologic conditions in the body such that the degradation products are excretable or absorbable by the body.
In the present application, the term “non biodegradable” is defined to include both non bioabsorbable and non bioresorbable materials. By non biodegradable, it is meant that the materials do not decompose under body conditions and remain permanently in the body.
Adhesion barrier films are known, that are obtained via gelling of a starting solution comprising collagen. The collagen may be derived from animal or human sources. Anyway, prosthesis involving animal human derived biological materials are not always reproducible or compatible.
Moreover, it was found that the films of the prior art used as a barrier for the prevention of post-surgical adhesions may lack mechanical strength and resistance, and may delaminate once implanted. The film therefore separates from the prosthetic fabric within the body of the patient and can not perform its adhesion barrier function.
There is therefore a need for a prosthesis that would be entirely synthetic and that would comprise a fully biodegradable adhesion barrier film, said film being nevertheless resistant to delamination at least for the time necessary for it to prevent occurrence of adhesions, namely for at least 1 to 2 weeks.
In addition, in order to minimize the trauma subsequent to any surgical intervention, patients are increasingly operated by laparoscopy when the type of intervention performed allows this. Laparoscopy requires only very small incisions through which a trocar is passed, with the prosthesis being conveyed inside the trocar to the implantation site. Open surgery is thus avoided, and the patient can soon leave hospital. Laparoscopy is particularly popular in surgical interventions performed in the abdomen, for example the treatment of hernias.
However, the trocars used in laparoscopic surgery generally have a relatively small calibrated diameter, which may vary, for example, from 5 to 15 mm, in order to reduce as much as possible the size of the incision that is made. The prosthesis therefore has to be conveyed to the implantation site within a conduit of small diameter. The prosthesis is generally rolled up on itself in order to make it slide in the conduit of the trocar or is introduced directly by force, if appropriate with the aid of laparoscopy forceps.
There is therefore still the need for a prosthesis based on a knit provided with a biodegradable adhesion barrier film on one of its faces, that is soft enough to be pliable and to be foldable so that it can be easily introduced into a conduit such as that of a trocar of small diameter, without damaging the knit and the film.
Moreover, reinforcement prostheses are all the more effective and their local tolerance is all the better, the earlier and the more intimate their tissue integration. For this reason, the most effective of the known prosthetic fabrics for these indications are generally porous and are designed in such a way as to be integrated in the body as rapidly as possible.
In the present application, the term “porous” is intended to signify the characteristic according to which the faces and the thickness of the textile it refers to, such as a fabric or a knit, present pores, voids, alveoli, distributed regularly or irregularly, and promoting all cell colonization, on the surface and within/through the thickness of the textile.
In the present application, the term «non-porous» is intended to signify that the structure it refers to, such as a film, presents a smooth and even surface devoid of any pores, such a surface preventing the occurrence of postsurgical adhesions.
Moreover, in a view of reducing the foreign material implanted into the body of a patient, it is desired to produce lightweight reinforcement prostheses. In addition, for facilitating the work of the surgeon at the time he puts the prosthesis in place at the implantation site, it is further desired that the prosthesis show a good transparency. Lightweight knits showing a plurality of pores, and preferably large pores, are therefore desirable for forming lightweight reinforcement prostheses favoring a good tissue ingrowth.
There is therefore a need for a synthetic prosthesis that could be used for tissue reinforcement, for example for the reinforcement of soft tissue where a weakness exists such as the primary abdominal wall and incisional hernias, in an intraperitoneal position, possibly by laparoscopy, that would offer cell recolonization and tissue integration properties on one of its faces, while being provided on its other face with a biodegradable adhesion barrier film preventing or at least minimizing postsurgical adhesions, at least during the 4 weeks following surgery, said film being not subject to delamination. The synthetic prosthesis should also preferably minimize the amount of foreign material implanted in the body of the patient.
A first aspect of the invention is a synthetic prosthesis for tissue reinforcement comprising:
wherein said binder is present between said film and said first face under the form of a discontinuous layer, and
wherein said second face of said porous knit is left open to cell colonization.
The prosthesis of the invention comprises two faces which are different in their respective appearances and functions, namely one face which is porous or open on one side, in order to accommodate and direct the postsurgical cell colonization, and the other face which is closed, for tissue separation without adhesion at least during the time post-surgical adhesions are likely to occur.
The prosthesis of the invention allows therefore cell colonization and tissue integration to take place on one hand, via the second face of the porous knit, while minimizing the development of adhesions on its opposite face, namely the first face of the knit which is covered by the non porous biodegradable film acting as an adhesion barrier film for at least 1 to 2 weeks.
The film is intimately linked to the first face of the knit by the binder, and cannot be delaminated, while at the same time maintaining the porosity open on the second surface of the knit.
Moreover, the cooperation of the knit, the film and the binder of the prosthesis of the invention makes it possible for tissue colonization to develop immediately, independently of complete degradation of the biodegradable film, which itself is relatively rapid, for example occurring in about 4 to 15 weeks without compromising the performance of the prosthesis. In addition, the structure of the binder, which is present under the form of a discontinuous layer of material, allows the cell colonization and tissue integration to further develop on the first face of the porous knit when the non porous film begins biodegrade after a few weeks, at a time when post-surgical adhesions are no more likely to occur and the non porous film has completed its function of prevention of adhesions.
The prosthesis of the invention is formed of synthetic materials only. Synthetic materials have the advantage of being reproducible and their behavior is well known.
In addition, the presence of a common chemical component, such as ε-polycaprolactone, both in the non porous film and in the binder of the prosthesis of the invention allows reducing the number of foreign materials of different compositions that are implanted in the body of the patient.
The prosthesis of the invention is particularly adapted to the reinforcement of abdominal wall soft tissue where a weakness exists in procedures involving primary and incisional abdominal wall hernia surgeries.
The prosthesis of the invention comprises a porous knit made from a monofilament of a synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face.
The knit of the invention is made from a monofilament of a synthetic biocompatible material.
The synthetic biocompatible material may be biodegradable, non-biodegradable or a combination of biodegradable and non-biodegradable, depending on the desired duration of the reinforcement function of the prosthesis.
If a non permanent reinforcement is desired, the synthetic biocompatible material may be biodegradable. A suitable synthetic biocompatible material may be polylactic acid or copolymers thereof.
If a permanent reinforcement is desired the synthetic biocompatible material may be non biodegradable.
In embodiments, the synthetic biocompatible material is a synthetic non-biodegradable material. Embodiments where the synthetic biocompatible material is non-degradable allow a long term reinforcement of the tissue to be reinforced or repaired.
In embodiments, the biocompatible polymer material is selected from polypropylene, polyethylene terephthalate, and mixtures thereof.
In embodiments, the biocompatible polymer material is polypropylene.
In embodiments, the monofilament has a diameter of from about 0.08 mm to about 0.25 mm, preferably from about 0.10 mm to 0.15 mm, more preferably of about 0.11 mm, 0.12 mm, or 0.13 mm, more preferably 0.12 mm. Such a diameter allows obtaining a good size of the pores and providing the knit with a lightweight and flexible structure, while maintaining good mechanical properties. In embodiments, the monofilament has a diameter of about 0.12 mm.
The knit of the prosthesis of the invention is porous. Knits may comprise openings or pores which may be generated by the pattern followed for the knitting of yarns forming the knit.
In embodiments, the knit of the prosthesis of the invention comprises a plurality of pores having a diameter above 1 mm. In particular, the plurality of pores having a diameter above 1 mm defines an efficient porosity of said knit ranging from about 35% to about 70%, preferably of about 55%.
By “efficient porosity” is meant according to the present application a porosity taking into account only the pores having a diameter above 1 mm, while leaving out the pores having a diameter less or equal to 1 mm. By “pores having a diameter above 1 mm” is meant the pores which have dimensions greater than 1 mm in all directions. The efficient porosity therefore corresponds to the ratio of the area of the totality of the pores having a diameter above 1 mm as defined above to the area of the totality of the knit studied. The pores having a diameter above 1 mm are measured with a profile projector such as a projector 300V from ORAMA. The “efficient porosity” and its measuring method are described in the publication “New objective measurements to characterize the porosity of textile implants”, T. Mühl, M. Binnebösel, U. Klinge and T. Goedderz, Journal of Biomedical Materials Research Part B: Applied Biomaterials, p. 176-183.
The efficient porosity as described above is useful for characterizing the ability of the knit of the prosthesis of the invention to favor cell colonization. Indeed, pores having a diameter above 1 mm are particularly desired for tissue ingrowth after implantation.
In embodiments, the knitting pattern of the knit of the prosthesis of the invention defines a plurality of pores having a diameter ranging above 1 mm. The pores may have a substantially hexagonal or circular shape.
In embodiments, the knit of the invention comprises a plurality of pores having a diameter above 2 mm. Such knits with pores having a diameter above 2 mm favor cell colonization and exhibit a good transparency allowing the surgeon to have a better visibility of the surrounding tissues when he puts the knit/prosthesis in place at the implantation site.
A suitable porous knit for the prosthesis of the invention is for example a knit based on a monofilament of polypropylene of diameter 0.12 mm, the pattern followed for the knitting of said monofilament on a knitting machine having two guide bars B1, B2 being the following, according to the ISO 11676 standard:
Guide bars B1 and B2 may be threaded 1 full 1 empty and may move symmetrically.
The knitting machine may be a warp knitting machine or a raschel knitting machine.
Another suitable knit for the prosthesis of the invention is obtained by knitting a monofilament of polypropylene of diameter 0.10 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:
Bar B1: 5.4/4.3/2.1/0.1/1.2/3.4//
Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//
Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.
The two above knitting patterns allow obtaining knits suitable for the present invention, having a plurality of pores having a diameter above 1 mm, an efficient porosity ranging from about 35% to about 70%, and a transparency allowing the surgeon to have a good visibility of the implantation site at the time he puts the knit or prosthesis in place.
The knit of the prosthesis of the invention is preferably lightweight. The knit of the prosthesis of the invention preferably shows a mass per unit area ranging from about 30 to about 70 g/m2, preferably ranging from about 36 to about 50 g/m2, and more preferably of about 44 g/m2, 45 g/m2, 46 g/m2, 47 g/m2 or 48 g/m2, measured according to ISO 3801: 1977 «Determination of mass per unit length and mass per unit area», 5 specimens 1 dm2. Such a low mass per unit area allows introducing only a little quantity of foreign material in the body of the patient.
In embodiments, the knit of the prosthesis of the invention has a tensile breaking strength in the warp direction of at least about 200 N, preferably of about 237 N. In embodiments, the knit of the prosthesis of the invention has a tensile breaking strength in the weft direction of at least about 170 N, preferably of about 201 N. In embodiments, the knit of the invention has a bursting strength of at least about 400 kPa, preferably of about 463 kPa. In embodiments, the knit of the prosthesis of the invention has a tear strength in the warp direction of at least about 25 N, preferably of about 30 N. In embodiments, the knit of the prosthesis of the invention has a tear strength in the weft direction of at least about 25 N, preferably of about 37 N. In embodiments, the knit of the prosthesis of the invention has a suture pull out strength in the warp direction of at least about 35 N, preferably of about 46 N. In embodiments, the knit of the prosthesis of the invention has a suture pull out strength in the weft direction of at least about 38 N, preferably of about 42 N. In embodiments, the knit of the prosthesis of the invention has a tensile strength of at least about 42 N/cm, preferably of about 47 N/cm.
The tensile breaking strength (N), the bursting strength (kPa), the tear strength (N), the suture pull out strength (N) and the tensile strength (N/cm) above are measured according to the methods as indicated in the below Examples of the present application.
The porous knit of the prosthesis of the invention shows preferably an homogeneous distribution of shear forces at fixation points. In particular, although it is provided with a lightweight structure, the porous knit of the prosthesis of the invention may show a good resistance to fracture at fixation points compared to lightweight knits of the prior art.
The prosthesis of the invention further comprises a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone. The film is intended to cover at least part of the first face of the knit. In embodiments, the synthetic non porous biodegradable film of the prosthesis of the invention entirely covers the first face of the porous knit, and more preferably projects beyond the edges of the knit in such a way as to protect the prosthesis from contacts with adjacent biological tissues, the overshoot being from 5 to 10 millimeters for example. The synthetic non porous biodegradable film of the prosthesis of the invention is intended to minimize post-surgical adhesions on the first face of the knit by occluding the pores present on the surface of said first face. The synthetic non porous biodegradable film of the prosthesis of the invention is preferably continuous and has a smooth and even surface.
In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition comprising at least a copolymer of at least ε-caprolactone. In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition comprising, preferably consisting in, a random copolymer of glycolide, ε-caprolactone, trimethylene carbonate and lactide.
In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition consisting in a random copolymer of from about 68.5 to about 71.5 mole percent glycolide, from about 14.7 to about 17.5 mole percent ε-caprolactone, from about 6.7 to about 8.6 mole percent trimethylene carbonate and from about 4.6 to about 6.5 mole percent lactide. The preparation of copolymer composition suitable for forming the film of the prosthesis of the invention is described in U.S. Pat. No. 6,235,869.
The film may be obtained by flat-die extrusion of the composition comprising at least a copolymer of at least ε-caprolactone in an extruder at a temperature ranging from 170° C. to 210° C. Further to extrusion, the film may be annealed according to conventional methods.
The film of the prosthesis of the invention is biodegradable. In embodiments, the film of the prosthesis of the invention preferably degrades in vivo in less than 15 weeks. A film with such degradation kinetics allows limiting the presence of foreign material within the body of the patient while being efficient with regard to prevention of post-surgical adhesions.
In embodiments, the synthetic non porous biodegradable film shows a thickness ranging from about 15 μm to about 25 μm. In embodiments, the thickness of the film is about 20 μm. In embodiments, the thickness of the film is about 25 μm. Films with such thicknesses constitute efficient adhesion barriers with limited risk of inflammatory response. In addition, films with such thicknesses allow the resulting prosthesis to remain globally thin and soft, and therefore particularly adapted to be folded for easy introduction in a trocar.
The prosthesis of the invention further comprises a synthetic biodegradable binder for bonding the film to the first face of the knit. The binder comprises at least a polymer of ε-caprolactone.
In embodiments, the binder consists in a polymer of ε-caprolactone, in particular in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol. Such a polymer of ε-caprolactone allows a good binding of the film to the first face of the knit even if the polymer of ε-caprolactone is present in a limited amount. Such a polymer of ε-caprolactone therefore allows obtaining an efficient binding of the film to the first face of the knit while limiting the amount of foreign materials introduced in the body of the patient.
In embodiments, in particular where the binder consists in a polymer of ε-caprolactone, for example in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol, the binder is present in the prosthesis, in particular between the film and the first face of the knit, in an amount ranging from about 0.60 mg/cm2 to about 0.95 mg/cm2, preferably ranging from about 0.70 mg/cm2 to about 0.85 mg/cm2, more preferably of about 0.83 mg/cm2.
In embodiments, in particular where the binder consists in a polymer of ε-caprolactone, for example in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol, the binder is present in an amount ranging from 6% to 11% by weight, with respect to the weight of the prosthesis. The binder therefore represents a limited amount of the weight of the prosthesis and a limited amount of additional foreign material introduced in the body of the patient.
The binder is present between said film and said first face under the form of a discontinuous layer. By “discontinuous layer of material” is meant in the present application a plurality of discrete amounts of material which are not linked to each other and which do not form a continuous film. The binder of the prosthesis of the invention is present between said film and said first face under the form of a plurality of discrete amounts of binder which are not linked to each other and which do not form a continuous film. For example, the presence of the binder on the first face of the knit may be limited to the surface of the fibers of the monofilament forming the knit, preferably on the top surface of such fibers, with no binder present in the pores of the knit. In addition, preferably, no binder material is present on the surface of the second face of the knit. The binder therefore may not form a continuous layer between the first face of the knit and the film.
When the binder consists in a polymer of ε-caprolactone, the prosthesis comprises a limited number of different chemical materials, as ε-caprolactone is also a component of the film. This allows limiting the number of different foreign materials introduced in the body of the patient.
A polymer of ε-caprolactone having a molecular weight of about 80000 g/mol suitable for the binder of the prosthesis of the invention is the product commercially available under the code 440744 from company Sigma-Aldrich.
The non porous film of the prosthesis of the invention is intimately linked to the first face of the knit by the binder, although the amount of binder per surface area on the first face of the knit is limited and although the binder may be present under the form of a discontinuous layer.
The prosthesis of the invention may be further provided with one or more marking(s) bearing information that may be useful to the surgeon, in particular at the time of selecting the prosthesis and/or at the time of positioning the prosthesis inside the body of the patient. For example, the marking may indicate the size of the prosthesis, the direction of the longitudinal axis or transversal axis in case the prosthesis is rectangular, the center of the prosthesis, etc. . . . The marking may also indicate to the surgeon the face of the prosthesis which is open to cell colonization or, on the contrary, the face that is covered by the film for minimizing post-surgical adhesions.
In embodiments, the prosthesis is provided with at least a marking made of a synthetic biodegradable material. In embodiments, the marking is located between the binder and the film. In other embodiments, the marking is located between the first face of the knit and the binder. The marking may be present under the form of one piece of marking or several pieces of markings, like letters, digits, spots, dots, geometric figures and the like. In the present application the expression “marked zone” will refer to a zone of the prosthesis, in particular of the first face of the knit, where at least a piece of marking is present.
In embodiments, the total surface area of the marked zones of the prosthesis on a face of the prosthesis may represent from about 0.8% to about 4% of the total surface area of said face of the prosthesis.
In embodiments, the marking is made from a composition consisting in a dye solubilized in a solution of a polymer of ε-caprolactone. In other embodiments, the marking is made from a composition consisting in a dye solubilized in a solution of a copolymer of lactic acid and glycolic acid.
In embodiments, the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, for example D&C Violet N° 2. In embodiments, the weight ratio of the dye, for example D&C Violet N° 2, to the polymer of ε-caprolactone is equal or less than 1/1000.
In embodiments where the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, in particular D&C Violet N° 2, the synthetic biodegradable material forming the marking is present, in particular between the first face of the knit and the binder, in an amount ranging from about 3.2 mg/cm2 to about 4.0 mg/cm2, in the marked zones of the prosthesis.
When the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and D&C Violet N° 2, and when the binder consists in a polymer of ε-caprolactone, the amount of polymer of ε-caprolactone and D&C Violet N° 2 in the marked zones of the prosthesis may range from 3.7 mg/cm2 to about 4.6 mg/cm2. In such embodiments, the amount of polymer of ε-caprolactone in the marked zones of the prosthesis remains limited.
When the synthetic biodegradable material forming the marking consists in polymer of ε-caprolactone and a dye, the prosthesis comprises a limited number of different chemical materials, as ε-caprolactone is also a component of the film and of the binder. This allows limiting the number of different foreign materials introduced in the body of the patient.
In addition, when the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, the degradation kinetics of the synthetic biodegradable material forming the marking is very close to that of the binder. The degradation process of the synthetic biodegradable material forming the marking and of the binder are therefore similar and do not affect each other.
Another aspect of the invention is a method for forming the prosthesis above comprising the following steps:
In a first step of the method of the invention, step a), a porous knit made from a monofilament of a synthetic biocompatible material is provided. Suitable porous knits for the prosthesis of the invention and the method for manufacturing them is described above in the present application.
Following knitting, the knit may be heat-set, for example on a heat-setting machine according to conventional methods.
In a second step of the method of the invention, step b), a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone is provided. Suitable films for the prosthesis of the invention and their manufacture method are described above.
In a third step of the method of the invention, step c), the first face of the knit obtained in step a) is glued with a binding solution so as to form a discontinuous layer of binding solution on the first face of the knit.
In embodiments, a composition of a polymer of ε-caprolactone in a solvent such as methylene chloride is used for binding the film to the first face of the knit. For example, the composition is sprayed on the first face of the knit in order to glue said first face of the knit.
In embodiments, the binding solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride. For example, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for binding the film to the first face of the knit.
In embodiments, the spraying is performed with a spraying machine «SONOTEK Flexicoat» with a microflow pump. In embodiments, the spraying step may comprise several repeated passes of the spraying nozzle on the first face of the knit.
In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit. In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit so as to form a discontinuous layer of binding solution. In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit at a delivery rate of the solution of about 10 mL/min. The spraying may be repeated several times. For example, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit via 3 passes of a spraying nozzle, with a delivery rate of the solution of about 10 mL/min for each pass.
In embodiments, during the spraying and subsequent natural drying, the solvent, in particular the methylene chloride, evaporates totally. The binder left on the first face of the knit therefore consists in the polymer of ε-caprolactone.
The spraying conditions of the binding solution, in particular a delivery rate of the solution of about 10 mL/min, allows the binding solution, and in the end the remaining binder after complete evaporation of the solvent such as methylene chloride, to be distributed on the surface of the first face of the knit under the form of a discontinuous layer, and in particular on top of the monofilament fibers of the surface of the first face of the knit, with no binding solution/binder present in the pores present at the surface of said first face of the knit, and with no binding solution/binder present on the surface of the second face of the knit.
In addition, such spraying conditions, for example a delivery rate of the solution of about 10 mL/min and a number of 3 passes, allow obtaining a limited amount of binder in the final product, namely the prosthesis, such as an amount ranging from about 0.60 mg/cm2 to about 0.95 mg/cm2, preferably ranging from about 0.70 mg/cm2 to about 0.85 mg/cm2, more preferably of about 0.83 mg/cm2 between the film and the first face of the knit.
In a fourth step of the method of the invention, step d), the film of step b) is laminated on the glued face of the knit.
The lamination may be performed on a press machine comprising a bottom plate and a top heating plate.
In embodiments, the lamination step is performed by contacting the film of step b) with the glued face of the knit obtained at step c) during a time period ranging from about 30 s to about 7 min, preferably of about 5 minutes, at a temperature of about 105° C. with a contact pressure ranging from about 137895 Pa (20 psi) to about 1034213 Pa (150 psi), preferably of about 172369 Pa (25 psi).
For example, the knit may be positioned on the bottom plate of the machine, with the glued face of the knit in the upward direction. The film obtained at steb b) may then be positioned on the glued face of the knit. The temperature of the top heating plate may be set at about 105° C. The heating plate may be left in contact with the knit and film at the desired contact pressure, for example about 172369 Pa (25 psi), during the desired time period, for example a time period of about 5 minutes.
The method of the invention allows obtaining an efficient bonding of the film to the knit without having to glue the film itself. An additional step of gluing the film is therefore avoided with the method of the invention. The method is therefore simplified with respect to existing methods in which the film needs to be also glued.
In particular, the gluing step conditions and the lamination step conditions of the method of the invention combined with the use of a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride as the binding solution allow obtaining an intimate binding between the film and the first face of the knit, although the amount of binder per surface area between the film and the first face of the knit in the resulting prosthesis may be limited and although the binder in the resulting prosthesis may be present under the form of a discontinuous layer between the film and said first face.
The resulting prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient.
Before gluing the first face of the knit in view of laminating the film, a printing step may be performed in order to provide the first face of the knit with one or more marking(s).
In embodiments, the printing step comprises positioning a mask on the first face of the knit and spraying a dying solution on the first face of the knit provided with said mask. The mask generally is designed so as to allow one or more part(s) of the first face of the knit to receive the dying composition and therefore be printed while protecting the rest of the surface of said first face. The mask therefore may be designed so as to allow the printing of any desired geometric figures, such as letters, figures, etc. . . . on the first face of the knit.
In embodiments, a composition of a polymer of ε-caprolactone in a solvent such as methylene chloride is used for solubilizing a dye intended to be used as a marking for the prosthesis of the invention. The composition may be sprayed on the first face of the knit provided with a mask. One or more marking(s) are therefore obtained.
In embodiments, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for solubilizing 0.03 g/L of dye. In embodiments, the dye is D&C Violet N° 2. In embodiments, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for solubilizing 0.03 g/L of D&C Violet N° 2. Such a solution corresponds to a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone.
In embodiments, the dying solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone.
In embodiments, the spraying is performed with a spraying machine «SONOTEK Flexicoat» with a microflow pump. In embodiments, the spraying step may comprise repeated passes of the spraying nozzle on the first face of the knit provided with the mask.
In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed on the surface of the first face of the knit provided with the mask. In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed on the surface of the first face of the knit provided with the mask with a delivery rate of the solution of about 10 mL/min.
The spraying may be repeated several times depending on the color intensity that is desired for the marking. In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed via 13 passes of a spraying nozzle on the surface of the first face of the knit provided with the mask, with a delivery rate of the solution of about 10 mL/min.
In embodiments, during the spraying and subsequent natural drying, the solvent, in particular the methylene chloride, evaporates totally. The marking left on the first face of the knit once the mask is removed therefore consists in the polymer of ε-caprolactone and the D&C Violet N° 2.
Such an amount of dying composition and conditions for the printing step allow having simultaneously an efficient marking regarding colorimetric intensity, so that the marking may be easily seen by the surgeons, and a limited amount of foreign materials within the patient body.
In addition, such spraying conditions allow obtaining a limited amount of marking material in the final product, namely the prosthesis, such as an amount ranging from about about 3.2 mg/cm2 to about 4.0 mg/cm2 in the marked zones of the knit.
The prosthesis of the invention may be packaged and sterilized using conventionally known techniques.
The prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient. The prosthesis of the invention is also particularly efficient regarding cell colonization. The efficient porosity of the porous knit allows an optimal tissue integration on the second face of the knit.
Moreover, the prosthesis of the invention is soft and easily foldable. The prosthesis of the invention may therefore be easily introduced into a trocar and is particularly adapted in laparoscopy surgery.
The prosthesis of the invention can be implanted in intraperitoneal site for ventral hernia repair via open or laparoscopic approach. Fixation to the surrounding tissues can be achieved by stapling, conventional sutures or other means.
Another aspect of the invention is a hernia prosthesis comprising a knit as described above.
The present invention will become clearer from the following Examples and drawing in which:
In all the below examples, the polymer of ε-caprolactone used is a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol commercially available under the product code 440744 from company Sigma-Aldrich.
The present example describes the manufacture of knits suitable for the prosthesis of the invention.
1°) Manufacture of Porous Knit A:
Knit A is produced by knitting on a warp knitting machine or a raschel knitting machine having two guide bars B1, B2, a monofilament of polypropylene of diameter 0.12 mm, the pattern followed for the knitting of the monofilament being the following, according to the ISO 11676 standard:
Bar B1: 1.2/4.5/4.3/4.5/4.3/1.0/1.2/1.0//
Bar B2: 4.3/1.0/1.2/1.0/1.2/4.5/4.3/4.5//
Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.
The knitting pattern of Knit A produces pores greater than about 1.0 mm in diameter. For example, some pores of Knit A have an average size of 2.0×2.4 mm. Such a large size of pores is very favorable for cell colonization and confers to Knit A a good transparency allowing a good visibility at the implantation site.)
2°) Manufacture of Porous Knit B:
Knit B is obtained by knitting a monofilament of polypropylene of diameter 0.10 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:
Bar B1: 5.4/4.3/2.1/0.1/1.2/3.4//
Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//
Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.
After knitting, the knits A and B are heat-set according to conventional methods.)
3°) Properties of Knits A and B:
The following properties of knits A and B have been determined as follows:
The results are collected in the following tables:
The present example describes the preparation of a marked knit suitable for the prosthesis of the invention.
Knit A of Example 1 is provided with markings in accordance with the following method:
a) Preparation of the Dying Solution:
A mother solution of 0.1% (w/v) of dye in methylene chloride is first prepared as follows: 200 mg of D&C Violet N° 2 are added to 200 mL of methylene chloride with mixing.
The dying solution, under the form of a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone is then prepared as follows:
18 mL of the mother solution of 0.1% (w/v) of dye in methylene chloride is added to 582 mL of methylene chloride. 18 g of polymer ε-caprolactone are added to the solution with mixing. The mixing is continued until total solubilization of the polymer of ε-caprolactone.
b) Spraying of the Dying Solution:
A mask provided with void zones and filled zones is positioned on a first face of Knit A, namely on the face of Knit A on which it is intended to apply the adhesion barrier film in a subsequent step. The filled zones of the mask are intended to protect the zones of the first face of Knit A that are not intended to be marked. The filled zones of the mask will therefore prevent these zones of the first face of Knit A to be contacted by the dying solution and to be printed. The void zones of the mask are intended to allow the dying solution to reach the zones of the first face of Knit A that are intended to be marked. To the void zones of the mask will correspond the marked zones of the first face of Knit A.
The dying solution prepared in a) above is then sprayed on the first face of Knit A provided with the mask according to the following method: the spraying is performed with an ultrasonic spraying machine «SONOTEK Flexicoat» with a Sonotek 48 KHz Impact Nozzle and a microflow pump with the following conditions:
The spraying is performed under the form of 13 passes of the spraying nozzle. During the spraying, the methylene chloride totally evaporates.
At the end of the 13 passes of the spraying nozzle, and after evaporation of the methylene chloride, the synthetic biodegradable material forming the marking, namely the polymer ε-caprolactone and D&C Violet N° 2, is present on the first face of Knit A in an amount of about 3.50 mg/cm2 in the marked zones of the first face of Knit A.
Such an amount of marking material allows having simultaneously an efficient marking regarding colorimetric intensity, so that the marking may be easily seen by the surgeons, and a limited amount of foreign materials within the patient body.
The present example describes the manufacture of a sample of a prosthesis of the invention according to the method of the invention.)
1°) Gluing of Knit A:
The first face of Knit A with marked zones as obtained at EXAMPLE 2 above is glued with a binding solution in accordance with the following method:
A solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride is prepared as the binding solution.
The binding solution is then sprayed on the first face of Knit A provided with marked zones according to the following method: the spraying is performed with an ultrasonic spraying machine «SONOTEK Flexicoat» with a Sonotek 48 KHz Impact Nozzle and a microflow pump with the following conditions:
The spraying is performed under the form of 3 passes of the spraying nozzle. During the spraying, the methylene chloride totally evaporates.
Such spraying conditions of the binding solution, in particular a delivery rate of the solution of 10 mL/min, allow the binding solution, and in the end the binder after complete evaporation of the methylene chloride, to be distributed under the form of a discontinuous layer on the surface of the first face of the knit. Indeed, these spraying conditions allow only a limited amount of binding solution to be spread on the first face of Knit A at each pass of the nozzle. The binding solution is therefore not drawn downwards by gravity at each pass and remains significantly on the top surface of the fibers of the face of the knit on which it is sprayed. Thanks to these spraying conditions, the binding solution does not migrate towards the opposite face (second face) of the knit. The binder therefore remains present at the surface of the first face of Knit A and is available for completing an efficient bonding of the film to the first face of the knit once the lamination step is completed (see below).
For example, with spraying conditions where the solution rate is 20 mL/min at each pass of the nozzle, the binding solution is more prone to migrate towards the opposite face of the knit. Less binder is available in the end for performing the bonding between the first face of the knit and the film during the lamination step to come.
At the end of the 3 passes of the spraying nozzle at a delivery rate of the solution of 10 mL/min, and after evaporation of the methylene chloride, the binder, namely the polymer of ε-caprolactone, is present on the first face of Knit A in an amount of about 0.83 mg/cm2 in the non marked zones of the first face of Knit A.
At the end of the 3 passes of the spraying nozzle at a delivery rate of the solution of 10 mL/min, and after evaporation of the methylene chloride, the binder and the marking material, namely the polymer of of ε-caprolactone and D&C Violet N° 2, are present on the first face of Knit A in an amount of about 4.33 mg/cm2 in the marked zones of the first face of Knit A.
As will appear from the description below, such an amount of the binding solution allows obtaining an efficient binding of the film to the knit while limiting the amount of foreign materials in the body of the patient.)
2) Lamination of the Non Porous Film on the Glued Face of Knit A:
A rectangular shaped sample of the marked Knit A above of dimensions 10.5 cm×20.5 cm is prepared.
A non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone under the form of an extruded film obtained by flat-die extrusion of a composition consisting in a random copolymer of from about 68.5 to about 71.5 mole percent glycolide, from about 14.7 to about 17.5 mole percent ε-caprolactone, from about 6.7 to about 8.6 mole percent trimethylene carbonate and from about 4.6 to about 6.5 mole percent lactide, is provided. This film has a thickness of about 20 μm.
A rectangular shaped sample of the film above of dimensions 11 cm×22 cm is prepared.
The lamination is performed with a press from Nelipak comprising a bottom plate and a top heating plate.
The sample of Knit A is positioned on the bottom plate of the machine, with its glued face up.
The sample film is positioned on top of Knit A, so that the surface area on which the pressure is intended to be applied is 20.5 cm×8.5 cm.
A flap of about 3 cm of Knit A and of film is left out of the machine. This flap will not be laminated and will enable performing peel tests on the laminated sample.
The starting pressure of the machine is set up at 1.5 105 Pa (1.5 bar). The temperature of the top heating plate is set at about 105° C. The top heating plate is moved and put in contact with the film so as to press it against the glued face of the knit, and the efficient pressure exerted on the sample is about 172369 Pa (25 psi). The contact time is of 5 minutes.
A synthetic prosthesis of the invention is obtained. The film is intimately linked to the first face of Knit A by the binder, and cannot be delaminated, while at the same time maintaining the porosity open on the second surface of the knit. In particular, the film is intimately linked to the first face of Knit A by the binder, although the amount of binder per surface area on the first face of Knit A is limited.
In the present example, the binder is present in an amount of about 9% by weight, with respect to the weight of the prosthesis.
Wth reference to
The prosthesis 1 comprises a porous knit 2 (Knit A) made from monofilaments 3 of polypropylene as described above. The knit 2 defines two opposite faces, a first face 4 and a second face 5. The cross section of the knit 2 shown on
The prosthesis 1 further comprises a non porous biodegradable film 8, the film as described above, covering the first face 4 of the knit 2. The second face 5 of the knit is left open for cell colonization.
The film 8 is bonded to the first face 4 of the knit 2 by means of the binder 9. As appears on this figure, the binder 9 is under the form of a discontinuous layer of material. In particular, as explained above, the binder 9 is present under the form of a plurality of discrete amounts of binder material which are not linked to each other and which do not form a continuous film. No binder is present in the pores 7 of the knit 2 and no binder is present on the surface of the second face 5 of the knit 2.
The discrete structure of the binder 9 between the first face 4 of the knit 2 and the film 8 allows an improved global tissue integration of the prosthesis 1 after implantation. Indeed, the discontinuous structure of the binder 9 allows the cell colonization to further develop on the first face 4 of the knit 2 when the film 8 begins biodegrade after a few weeks, at a time when post-surgical adhesions are no more likely to occur and the film 8 has completed its function of prevention of adhesions. The cell colonization via the first face of the knit 2, after the non porous film 8 has begun its biodegradation, is therefore not impeded or delayed by the presence of the binder 9.
On
3°) Peeling Strength:
A peeling test was performed in order to check the peeling strength of the film and to check the efficiency of the bonding between the film and the first face of Knit A. The idea is to measure the energy necessary to peel the film. The higher the necessary energy, the more efficient the bonding between the film and the knit.
The peeling strength measuring method is the following: a traction machine with a bottom fixed jaw and a top mobile jaw is used. The load cell is of 50 N. The distance between the two jaws before the test begins is 3 cm.
A rectangular shaped sample of the knit above is prepared by cutting a strip of 2.54 cm width and 8.5 cm length in the knit above, with maintaining the 3 cm long flap. The free end of the knit of the 3 cm flap described above is grasped within the bottom jaw. The free end of the film of the 3 cm flap described above is grasped within the top jaw. The sample to be tested is placed towards the user of the machine. Before any testing, the jaws are blocked at a pressure of 4 bars to ensure safe grasping of the sample.
The test is performed with the following parameters:
During the testing, the mobile jaw moves away from the fixed jaw. The energy (mJ) necessary for separating the film from the knit with a displacement between 60 mm and 150 mm is measured. The maximum force (N) necessary for delaminating the sample is also measured.
The energy and the maximum force are measured as described above for 15 samples manufactured as described in the present example. The results are the following:
average energy for the 15 samples: 429±37 mJ,
average maximum force for the 15 samples: 6.4±0.6 N
These results confirm that the bonding of the film to the first face of Knit A is efficient. The film of the prosthesis of the invention is therefore very resistant to delamination.
Two prostheses, prosthesis P1 and prosthesis P2, were manufactured, both with the Knit A of Example 1 above, the binding solution of Example 3 above and the non porous film of Example 3 above.
For prosthesis P1, the gluing step was completed so as to form a discontinuous layer of the binding solution on the first face of the knit A.
For prosthesis P2, the gluing step was completed by spraying the binding solution both on the first face of the knit A and on the face of the non porous film, so that the binding solution was present between the first face of the knit and the film under the form of a continuous layer of material.
Prostheses P1 and P2 were then submitted to the lamination step.
The structure of the final products were as follows:
in prosthesis P1: the binder was present between the non porous film and the first face of knit A under the form of a discontinuous layer,
in prosthesis P2: the binder was present between the non porous film and the first face of knit A under the form of a continuous layer.
Prostheses P1 and P2 were further surgically implanted in direct contact with subcutaneaous tissue in rats for 4 weeks (9 sites per prosthesis).
Tissue integration of the prostheses was evaluated as follows: a tissue ingrowth score representing a composite score involving consideration of the degree and nature of ongoing inflammation, fibroplasias, fibrosis, angiogenesis, and encapsulation was defined. This parameter and tissue integration has a maximum score of 4 (1=adequate, 2=good, 3=very good, 4=excellent).
Results for P1: overall tissue ingrowth and integration of the implanted prosthesis was very good to excellent (scores ranging from 3 to 4).
Resultas for P2: overall tissue ingrowth and integration of the implanted prosthesis was good to excellent (scores ranging from 2 to 4)
The method of the invention allows obtaining an efficient bonding of film to the first face of the knit while minimizing the presence of foreign materials implanted into the body of the patient.
The resulting prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient.
The prosthesis of the invention is also particularly efficient regarding cell colonization. The efficient porosity of the knit, in particular of Knit A, allows an optimal tissue integration on the second face of the knit.
Moreover, the prosthesis of the invention is soft and easily foldable. The prosthesis of the invention may therefore be easily introduced into a trocar and is particularly adapted in laparoscopy surgery.
Number | Date | Country | Kind |
---|---|---|---|
15305947 | Jun 2015 | EP | regional |
This application is a divisional of U.S. patent application Ser. No. 15/169,829 filed Jun. 1, 2016, which claims the benefit of and priority to European Patent Application Serial No. 15305947.2 filed Jun. 19, 2015, and the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
1187158 | Mcginley | Jun 1916 | A |
3054406 | Usher | Sep 1962 | A |
3118294 | Van Laethem | Jan 1964 | A |
3124136 | Usher | Mar 1964 | A |
3272204 | Artandi et al. | Sep 1966 | A |
3276448 | Kronenthal | Oct 1966 | A |
3320649 | Naimer | May 1967 | A |
3364200 | Ashton et al. | Jan 1968 | A |
3570482 | Shigeru et al. | Mar 1971 | A |
3718725 | Hamano | Feb 1973 | A |
4006747 | Kronenthal et al. | Feb 1977 | A |
4060081 | Yannas et al. | Nov 1977 | A |
4173131 | Melton et al. | Nov 1979 | A |
4193137 | Heck | Mar 1980 | A |
4248064 | Odham | Feb 1981 | A |
4294241 | Miyata | Oct 1981 | A |
4307717 | Hymes et al. | Dec 1981 | A |
4338800 | Matsuda | Jul 1982 | A |
4476697 | Schafer et al. | Oct 1984 | A |
4487865 | Balazs et al. | Dec 1984 | A |
4500676 | Balazs et al. | Feb 1985 | A |
4511653 | Play et al. | Apr 1985 | A |
4527404 | Nakagaki et al. | Jul 1985 | A |
4591501 | Cioca | May 1986 | A |
4597762 | Walter et al. | Jul 1986 | A |
4603695 | Ikada et al. | Aug 1986 | A |
4631932 | Sommers | Dec 1986 | A |
4670014 | Huc et al. | Jun 1987 | A |
4709562 | Matsuda | Dec 1987 | A |
4748078 | Doi et al. | May 1988 | A |
4759354 | Quarfoot | Jul 1988 | A |
4769038 | Bendavid et al. | Sep 1988 | A |
4796603 | Dahlke et al. | Jan 1989 | A |
4813942 | Alvarez | Mar 1989 | A |
4841962 | Berg et al. | Jun 1989 | A |
4854316 | Davis | Aug 1989 | A |
4925294 | Geshwind et al. | May 1990 | A |
4931546 | Tardy et al. | Jun 1990 | A |
4942875 | Hlavacek et al. | Jul 1990 | A |
4948540 | Nigam | Aug 1990 | A |
4950483 | Ksander et al. | Aug 1990 | A |
4970298 | Silver et al. | Nov 1990 | A |
4976737 | Leake | Dec 1990 | A |
5002551 | Linsky et al. | Mar 1991 | A |
5015584 | Brysk | May 1991 | A |
5116357 | Eberbach | May 1992 | A |
5147374 | Fernandez | Sep 1992 | A |
5162430 | Rhee et al. | Nov 1992 | A |
5171273 | Silver et al. | Dec 1992 | A |
5176692 | Wilk et al. | Jan 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5195542 | Gazielly et al. | Mar 1993 | A |
5196185 | Silver et al. | Mar 1993 | A |
5201745 | Tayot et al. | Apr 1993 | A |
5201764 | Kelman et al. | Apr 1993 | A |
5206028 | Li | Apr 1993 | A |
5217493 | Raad et al. | Jun 1993 | A |
5254133 | Seid | Oct 1993 | A |
5256418 | Kemp et al. | Oct 1993 | A |
5258000 | Gianturco | Nov 1993 | A |
5263983 | Yoshizato et al. | Nov 1993 | A |
5304595 | Rhee et al. | Apr 1994 | A |
5306500 | Rhee et al. | Apr 1994 | A |
5324775 | Rhee et al. | Jun 1994 | A |
5328955 | Rhee et al. | Jul 1994 | A |
5334527 | Brysk | Aug 1994 | A |
5339657 | Mcmurray | Aug 1994 | A |
5350583 | Yoshizato et al. | Sep 1994 | A |
5356432 | Rutkow et al. | Oct 1994 | A |
5368549 | Mcvicker | Nov 1994 | A |
5368602 | Torre | Nov 1994 | A |
5370650 | Jonathan et al. | Dec 1994 | A |
5376375 | Rhee et al. | Dec 1994 | A |
5376376 | Li | Dec 1994 | A |
5397331 | Himpens et al. | Mar 1995 | A |
5399361 | Song et al. | Mar 1995 | A |
5413791 | Rhee et al. | May 1995 | A |
5425740 | Hutchinson, Jr. | Jun 1995 | A |
5428022 | Palefsky et al. | Jun 1995 | A |
5433996 | Kranzler et al. | Jul 1995 | A |
5441491 | Verschoor et al. | Aug 1995 | A |
5441508 | Gazielly et al. | Aug 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5456711 | Hudson | Oct 1995 | A |
5466462 | Rosenthal et al. | Nov 1995 | A |
5480644 | Freed | Jan 1996 | A |
5487895 | Dapper et al. | Jan 1996 | A |
5490984 | Freed | Feb 1996 | A |
5512291 | Li | Apr 1996 | A |
5512301 | Song et al. | Apr 1996 | A |
5514181 | Light et al. | May 1996 | A |
5522840 | Krajicek | Jun 1996 | A |
5523348 | Rhee et al. | Jun 1996 | A |
5536656 | Kemp et al. | Jul 1996 | A |
5543441 | Rhee et al. | Aug 1996 | A |
5565210 | Rosenthal et al. | Oct 1996 | A |
5567806 | Abdul-Malak et al. | Oct 1996 | A |
5569273 | Titone et al. | Oct 1996 | A |
RE35399 | Eisenberg | Dec 1996 | E |
5593441 | Lichtenstein et al. | Jan 1997 | A |
5595621 | Light et al. | Jan 1997 | A |
5601571 | Moss | Feb 1997 | A |
5607474 | Athanasiou et al. | Mar 1997 | A |
5607590 | Shimizu | Mar 1997 | A |
5614587 | Rhee et al. | Mar 1997 | A |
5618551 | Tardy et al. | Apr 1997 | A |
5634931 | Kugel | Jun 1997 | A |
5639796 | Lee | Jun 1997 | A |
5665391 | Lea | Sep 1997 | A |
5667839 | Berg | Sep 1997 | A |
5676967 | Williams et al. | Oct 1997 | A |
5681568 | Goldin et al. | Oct 1997 | A |
5686090 | Schilder et al. | Nov 1997 | A |
5686115 | Vournakis et al. | Nov 1997 | A |
5690675 | Sawyer et al. | Nov 1997 | A |
5695525 | Mulhauser et al. | Dec 1997 | A |
5697978 | Sgro | Dec 1997 | A |
5700476 | Rosenthal et al. | Dec 1997 | A |
5700477 | Rosenthal et al. | Dec 1997 | A |
5702416 | Kieturakis et al. | Dec 1997 | A |
5709934 | Bell et al. | Jan 1998 | A |
5711960 | Shikinami | Jan 1998 | A |
5716409 | Debbas | Feb 1998 | A |
5720981 | Eisinger | Feb 1998 | A |
5732572 | Litton | Mar 1998 | A |
5743917 | Saxon | Apr 1998 | A |
5749895 | Sawyer et al. | May 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5766246 | Mulhauser et al. | Jun 1998 | A |
5766631 | Arnold | Jun 1998 | A |
5769864 | Kugel | Jun 1998 | A |
5771716 | Schlussel | Jun 1998 | A |
5785983 | Furlan et al. | Jul 1998 | A |
5800541 | Rhee et al. | Sep 1998 | A |
5814328 | Gunasekaran | Sep 1998 | A |
5833705 | Ken et al. | Nov 1998 | A |
5840011 | Landgrebe et al. | Nov 1998 | A |
5861034 | Taira et al. | Jan 1999 | A |
5863984 | Doillon et al. | Jan 1999 | A |
5869080 | Mcgregor et al. | Feb 1999 | A |
5871767 | Dionne et al. | Feb 1999 | A |
5876444 | Lai | Mar 1999 | A |
5891558 | Bell et al. | Apr 1999 | A |
5899909 | Claren et al. | May 1999 | A |
5906937 | Sugiyama et al. | May 1999 | A |
5910149 | Kuzmak | Jun 1999 | A |
5911731 | Pham et al. | Jun 1999 | A |
5916225 | Kugel | Jun 1999 | A |
5919232 | Chaffringeon et al. | Jul 1999 | A |
5919233 | Knopf et al. | Jul 1999 | A |
5922026 | Chin | Jul 1999 | A |
5931165 | Reich et al. | Aug 1999 | A |
5942278 | Hagedorn et al. | Aug 1999 | A |
5962136 | Dewez et al. | Oct 1999 | A |
5972022 | Huxel | Oct 1999 | A |
RE36370 | Li | Nov 1999 | E |
5993844 | Abraham et al. | Nov 1999 | A |
5994325 | Roufa et al. | Nov 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6001895 | Harvey et al. | Dec 1999 | A |
6008292 | Lee et al. | Dec 1999 | A |
6015844 | Harvey et al. | Jan 2000 | A |
6039686 | Robert | Mar 2000 | A |
6042534 | Gellman et al. | Mar 2000 | A |
6042592 | Schmitt | Mar 2000 | A |
6043089 | Sugiyama et al. | Mar 2000 | A |
6051425 | Morota et al. | Apr 2000 | A |
6056688 | Benderev et al. | May 2000 | A |
6056970 | Greenawalt et al. | May 2000 | A |
6057148 | Sugiyama et al. | May 2000 | A |
6063396 | Kelleher | May 2000 | A |
6066776 | Goodwin et al. | May 2000 | A |
6066777 | Benchetrit | May 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6077281 | Das | Jun 2000 | A |
6080194 | Pachence et al. | Jun 2000 | A |
6083522 | Chu et al. | Jul 2000 | A |
6090116 | D Aversa et al. | Jul 2000 | A |
6113623 | Sgro | Sep 2000 | A |
6120539 | Eldridge et al. | Sep 2000 | A |
6132765 | Dicosmo et al. | Oct 2000 | A |
6143037 | Goldstein et al. | Nov 2000 | A |
6153292 | Bell et al. | Nov 2000 | A |
6162962 | Hinsch et al. | Dec 2000 | A |
6165488 | Tardy et al. | Dec 2000 | A |
6171318 | Kugel et al. | Jan 2001 | B1 |
6174320 | Kugel et al. | Jan 2001 | B1 |
6176863 | Kugel et al. | Jan 2001 | B1 |
6179872 | Bell et al. | Jan 2001 | B1 |
6180848 | Flament et al. | Jan 2001 | B1 |
6197325 | Macphee et al. | Mar 2001 | B1 |
6197934 | Devore et al. | Mar 2001 | B1 |
6197935 | Doillon et al. | Mar 2001 | B1 |
6210439 | Firmin et al. | Apr 2001 | B1 |
6214020 | Mulhauser et al. | Apr 2001 | B1 |
6221109 | Geistlich et al. | Apr 2001 | B1 |
6224616 | Kugel | May 2001 | B1 |
6241768 | Agarwal et al. | Jun 2001 | B1 |
6258124 | Darois et al. | Jul 2001 | B1 |
6262332 | Ketharanathan | Jul 2001 | B1 |
6264702 | Ory et al. | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6270530 | Eldridge et al. | Aug 2001 | B1 |
6277397 | Shimizu | Aug 2001 | B1 |
6280453 | Kugel et al. | Aug 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6290708 | Kugel et al. | Sep 2001 | B1 |
6306079 | Trabucco | Oct 2001 | B1 |
6306424 | Vyakarnam et al. | Oct 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6319264 | Tormala et al. | Nov 2001 | B1 |
6328686 | Robert | Dec 2001 | B1 |
6334872 | Termin et al. | Jan 2002 | B1 |
6383201 | Dong | May 2002 | B1 |
6391060 | Ory et al. | May 2002 | B1 |
6391333 | Li et al. | May 2002 | B1 |
6391939 | Tayot et al. | May 2002 | B2 |
6408656 | Ory et al. | Jun 2002 | B1 |
6410044 | Chudzik et al. | Jun 2002 | B1 |
6413742 | Olsen et al. | Jul 2002 | B1 |
6425924 | Rousseau | Jul 2002 | B1 |
6428978 | Olsen et al. | Aug 2002 | B1 |
6436030 | Rehil | Aug 2002 | B2 |
6440167 | Shimizu | Aug 2002 | B2 |
6443964 | Ory et al. | Sep 2002 | B1 |
6447551 | Goldmann | Sep 2002 | B1 |
6447802 | Sessions et al. | Sep 2002 | B2 |
6448378 | Devore et al. | Sep 2002 | B2 |
6451032 | Ory et al. | Sep 2002 | B1 |
6451301 | Sessions et al. | Sep 2002 | B1 |
6454787 | Maddalo et al. | Sep 2002 | B1 |
6477865 | Matsumoto | Nov 2002 | B1 |
6479072 | Morgan et al. | Nov 2002 | B1 |
6485503 | Jacobs et al. | Nov 2002 | B2 |
6500464 | Ceres et al. | Dec 2002 | B2 |
6500777 | Wiseman et al. | Dec 2002 | B1 |
6509031 | Miller et al. | Jan 2003 | B1 |
6511958 | Atkinson et al. | Jan 2003 | B1 |
6514286 | Leatherbury et al. | Feb 2003 | B1 |
6514514 | Atkinson et al. | Feb 2003 | B1 |
6540773 | Dong | Apr 2003 | B2 |
6541023 | Andre et al. | Apr 2003 | B1 |
6548077 | Gunasekaran | Apr 2003 | B1 |
6554855 | Dong | Apr 2003 | B1 |
6559119 | Burgess et al. | May 2003 | B1 |
6566345 | Miller et al. | May 2003 | B2 |
6575988 | Rousseau | Jun 2003 | B2 |
6576019 | Atala | Jun 2003 | B1 |
6596002 | Therin et al. | Jul 2003 | B2 |
6596304 | Bayon et al. | Jul 2003 | B1 |
6599323 | Melican et al. | Jul 2003 | B2 |
6599524 | Li et al. | Jul 2003 | B2 |
6599690 | Abraham et al. | Jul 2003 | B1 |
6610006 | Amid et al. | Aug 2003 | B1 |
6613348 | Jain | Sep 2003 | B1 |
6616685 | Rousseau | Sep 2003 | B2 |
6623963 | Mueller et al. | Sep 2003 | B1 |
6630414 | Matsumoto | Oct 2003 | B1 |
6637437 | Hungerford et al. | Oct 2003 | B1 |
6638284 | Rousseau et al. | Oct 2003 | B1 |
6645226 | Jacobs et al. | Nov 2003 | B1 |
6652594 | Francis et al. | Nov 2003 | B2 |
6652595 | Nicolo | Nov 2003 | B1 |
6653450 | Berg et al. | Nov 2003 | B1 |
6656206 | Corcoran et al. | Dec 2003 | B2 |
6660280 | Allard et al. | Dec 2003 | B1 |
6669735 | Pelissier | Dec 2003 | B1 |
6670018 | Fujita et al. | Dec 2003 | B2 |
6682760 | Noff et al. | Jan 2004 | B2 |
6685714 | Rousseau | Feb 2004 | B2 |
6706684 | Bayon et al. | Mar 2004 | B1 |
6706690 | Reich et al. | Mar 2004 | B2 |
6712859 | Rousseau et al. | Mar 2004 | B2 |
6719795 | Bryan et al. | Apr 2004 | B1 |
6723335 | Moehlenbruck et al. | Apr 2004 | B1 |
6726660 | Hessel et al. | Apr 2004 | B2 |
6730299 | Tayot et al. | May 2004 | B1 |
6736823 | Darois et al. | May 2004 | B2 |
6736854 | Vadurro et al. | May 2004 | B2 |
6737371 | Planck et al. | May 2004 | B1 |
6743435 | Devore et al. | Jun 2004 | B2 |
6746458 | Cloud | Jun 2004 | B1 |
6752834 | Geistlich et al. | Jun 2004 | B2 |
6755868 | Rousseau | Jun 2004 | B2 |
6773723 | Spiro et al. | Aug 2004 | B1 |
6783554 | Amara et al. | Aug 2004 | B2 |
6790213 | Cherok et al. | Sep 2004 | B2 |
6790454 | Abdul et al. | Sep 2004 | B1 |
6800082 | Rousseau | Oct 2004 | B2 |
6833408 | Sehl et al. | Dec 2004 | B2 |
6835336 | Watt | Dec 2004 | B2 |
6852330 | Bowman et al. | Feb 2005 | B2 |
6869938 | Schwartz et al. | Mar 2005 | B1 |
6872227 | Sump et al. | Mar 2005 | B2 |
6893653 | Abraham et al. | May 2005 | B2 |
6896904 | Spiro et al. | May 2005 | B2 |
6926723 | Mulhauser et al. | Aug 2005 | B1 |
6936276 | Spiro et al. | Aug 2005 | B2 |
6939562 | Spiro et al. | Sep 2005 | B2 |
6949625 | Tayot | Sep 2005 | B2 |
6966918 | Schuldt-Hempe et al. | Nov 2005 | B1 |
6971252 | Therin et al. | Dec 2005 | B2 |
6974679 | Andre et al. | Dec 2005 | B2 |
6974862 | Ringeisen et al. | Dec 2005 | B2 |
6977231 | Matsuda | Dec 2005 | B1 |
6984392 | Bechert et al. | Jan 2006 | B2 |
6988386 | Okawa et al. | Jan 2006 | B1 |
7011688 | Gryska et al. | Mar 2006 | B2 |
7021086 | Ory et al. | Apr 2006 | B2 |
7022358 | Eckmayer et al. | Apr 2006 | B2 |
7025063 | Snitkin et al. | Apr 2006 | B2 |
7041868 | Greene et al. | May 2006 | B2 |
7060103 | Carr et al. | Jun 2006 | B2 |
RE39172 | Bayon et al. | Jul 2006 | E |
7070558 | Gellman et al. | Jul 2006 | B2 |
7087065 | Ulmsten et al. | Aug 2006 | B2 |
7094261 | Zotti et al. | Aug 2006 | B2 |
7098315 | Schaufler | Aug 2006 | B2 |
7101381 | Ford et al. | Sep 2006 | B2 |
7115220 | Dubson et al. | Oct 2006 | B2 |
7156804 | Nicolo | Jan 2007 | B2 |
7156858 | Schuldt-Hempe et al. | Jan 2007 | B2 |
7175852 | Simmoteit et al. | Feb 2007 | B2 |
7192604 | Brown et al. | Mar 2007 | B2 |
7207962 | Anand et al. | Apr 2007 | B2 |
7214765 | Ringeisen et al. | May 2007 | B2 |
7226611 | Yura et al. | Jun 2007 | B2 |
7229453 | Anderson et al. | Jun 2007 | B2 |
7252837 | Guo et al. | Aug 2007 | B2 |
7279177 | Looney et al. | Oct 2007 | B2 |
7331199 | Ory et al. | Feb 2008 | B2 |
7393319 | Merade et al. | Jul 2008 | B2 |
7556598 | Rao | Jul 2009 | B2 |
7594921 | Browning | Sep 2009 | B2 |
7614258 | Cherok et al. | Nov 2009 | B2 |
7615065 | Priewe et al. | Nov 2009 | B2 |
7662169 | Wittmann | Feb 2010 | B2 |
7670380 | Cauthen, III et al. | Mar 2010 | B2 |
7682381 | Rakos et al. | Mar 2010 | B2 |
7709017 | Tayot et al. | May 2010 | B2 |
7718556 | Matsuda et al. | May 2010 | B2 |
7732354 | Fricke et al. | Jun 2010 | B2 |
7785334 | Ford et al. | Aug 2010 | B2 |
7789888 | Bartee et al. | Sep 2010 | B2 |
7799767 | Lamberti et al. | Sep 2010 | B2 |
7806905 | Ford et al. | Oct 2010 | B2 |
7824420 | Eldridge et al. | Nov 2010 | B2 |
7828854 | Rousseau et al. | Nov 2010 | B2 |
7900484 | Cherok et al. | Mar 2011 | B2 |
7931695 | Ringeisen | Apr 2011 | B2 |
8052759 | Dupic et al. | Nov 2011 | B2 |
8079023 | Chen | Dec 2011 | B2 |
8100924 | Browning | Jan 2012 | B2 |
8123817 | Intoccia et al. | Feb 2012 | B2 |
8142515 | Therin et al. | Mar 2012 | B2 |
8157821 | Browning | Apr 2012 | B2 |
8157822 | Browning | Apr 2012 | B2 |
8182545 | Cherok et al. | May 2012 | B2 |
8197837 | Jamiolkowski et al. | Jun 2012 | B2 |
8206632 | Rousseau et al. | Jun 2012 | B2 |
8215310 | Browning | Jul 2012 | B2 |
8317872 | Adams | Nov 2012 | B2 |
8323675 | Greenawalt | Dec 2012 | B2 |
8343232 | Adzich et al. | Jan 2013 | B2 |
8366787 | Brown et al. | Feb 2013 | B2 |
8435307 | Paul | May 2013 | B2 |
8470355 | Skalla et al. | Jun 2013 | B2 |
8562633 | Cully et al. | Oct 2013 | B2 |
8574627 | Martakos et al. | Nov 2013 | B2 |
8709094 | Stad et al. | Apr 2014 | B2 |
8734471 | Deitch | May 2014 | B2 |
8753360 | Gleiman et al. | Jun 2014 | B2 |
8758800 | Stopek et al. | Jun 2014 | B2 |
8784294 | Goddard | Jul 2014 | B2 |
8814887 | Walther et al. | Aug 2014 | B2 |
8828092 | Toso et al. | Sep 2014 | B2 |
8834864 | Odar et al. | Sep 2014 | B2 |
8846060 | Archibald et al. | Sep 2014 | B2 |
8865215 | Ladet et al. | Oct 2014 | B2 |
8877233 | Obermiller et al. | Nov 2014 | B2 |
8911504 | Mathisen et al. | Dec 2014 | B2 |
8920370 | Sholev et al. | Dec 2014 | B2 |
8956373 | Ford et al. | Feb 2015 | B2 |
8962006 | Bayon et al. | Feb 2015 | B2 |
8968762 | Ladet et al. | Mar 2015 | B2 |
8979935 | Lozier et al. | Mar 2015 | B2 |
9034357 | Stopek | May 2015 | B2 |
9113993 | Lee | Aug 2015 | B2 |
9211175 | Stopek et al. | Dec 2015 | B2 |
9216075 | Bailly et al. | Dec 2015 | B2 |
20020087174 | Capello | Jul 2002 | A1 |
20020095218 | Carr et al. | Jul 2002 | A1 |
20030086975 | Ringeisen | May 2003 | A1 |
20030106346 | Matsumoto | Jun 2003 | A1 |
20030114937 | Leatherbury et al. | Jun 2003 | A1 |
20030133967 | Ruszczak et al. | Jul 2003 | A1 |
20030225355 | Butler | Dec 2003 | A1 |
20040034373 | Schuldt-Hempe et al. | Feb 2004 | A1 |
20040054376 | Ory et al. | Mar 2004 | A1 |
20040059356 | Gingras | Mar 2004 | A1 |
20040101546 | Gorman et al. | May 2004 | A1 |
20050002893 | Goldmann | Jan 2005 | A1 |
20050021058 | Negro | Jan 2005 | A1 |
20050085924 | Darois et al. | Apr 2005 | A1 |
20050113849 | Popadiuk et al. | May 2005 | A1 |
20050137512 | Campbell et al. | Jun 2005 | A1 |
20050142161 | Freeman et al. | Jun 2005 | A1 |
20050148963 | Brennan | Jul 2005 | A1 |
20050175659 | Macomber et al. | Aug 2005 | A1 |
20050232979 | Shoshan | Oct 2005 | A1 |
20050267521 | Forsberg | Dec 2005 | A1 |
20050288691 | Leiboff | Dec 2005 | A1 |
20060116696 | Odermatt et al. | Jun 2006 | A1 |
20060135921 | Wiercinski et al. | Jun 2006 | A1 |
20060147501 | Hillas et al. | Jul 2006 | A1 |
20060216320 | Kitazono et al. | Sep 2006 | A1 |
20060252981 | Matsuda et al. | Nov 2006 | A1 |
20060253203 | Alvarado | Nov 2006 | A1 |
20060282103 | Fricke et al. | Dec 2006 | A1 |
20070088391 | Mcalexander et al. | Apr 2007 | A1 |
20070129736 | Solecki | Jun 2007 | A1 |
20070198040 | Buevich et al. | Aug 2007 | A1 |
20070299538 | Roeber | Dec 2007 | A1 |
20080091276 | Deusch et al. | Apr 2008 | A1 |
20080109017 | Herweck et al. | May 2008 | A1 |
20080113001 | Herweck et al. | May 2008 | A1 |
20080172071 | Barker | Jul 2008 | A1 |
20080255593 | St-Germain | Oct 2008 | A1 |
20090035341 | Wagener et al. | Feb 2009 | A1 |
20090036996 | Roeber | Feb 2009 | A1 |
20090068250 | Gravagna et al. | Mar 2009 | A1 |
20090105526 | Piroli et al. | Apr 2009 | A1 |
20090163936 | Yang et al. | Jun 2009 | A1 |
20090187197 | Roeber et al. | Jul 2009 | A1 |
20090192530 | Adzich et al. | Jul 2009 | A1 |
20090204129 | Fronio | Aug 2009 | A1 |
20090216338 | Gingras et al. | Aug 2009 | A1 |
20090270999 | Brown | Oct 2009 | A1 |
20090281558 | Li et al. | Nov 2009 | A1 |
20090318752 | Evans et al. | Dec 2009 | A1 |
20100104608 | Abuzaina et al. | Apr 2010 | A1 |
20100318108 | Datta | Dec 2010 | A1 |
20110015760 | Kullas | Jan 2011 | A1 |
20110144667 | Horton et al. | Jun 2011 | A1 |
20110190795 | Hotter et al. | Aug 2011 | A1 |
20110238094 | Thomas et al. | Sep 2011 | A1 |
20110251699 | Ladet et al. | Oct 2011 | A1 |
20110257666 | Ladet et al. | Oct 2011 | A1 |
20120016388 | Houard et al. | Jan 2012 | A1 |
20120029537 | Mortarino | Feb 2012 | A1 |
20120065727 | Reneker et al. | Mar 2012 | A1 |
20120082712 | Stopek et al. | Apr 2012 | A1 |
20120116425 | Intoccia et al. | May 2012 | A1 |
20120150204 | Mortarino et al. | Jun 2012 | A1 |
20120165937 | Montanari et al. | Jun 2012 | A1 |
20120179175 | Hammell et al. | Jul 2012 | A1 |
20120179176 | Wilson et al. | Jul 2012 | A1 |
20120197415 | Montanari et al. | Aug 2012 | A1 |
20140005341 | Tang | Jan 2014 | A1 |
20140044861 | Boey et al. | Feb 2014 | A1 |
20140364684 | Lecuivre et al. | Dec 2014 | A1 |
Number | Date | Country |
---|---|---|
1317836 | May 1993 | CA |
201879864 | Jun 2011 | CN |
19544162 | Apr 1997 | DE |
19718903 | Dec 1997 | DE |
19751733 | Dec 1998 | DE |
19832634 | Jan 2000 | DE |
10019604 | Oct 2001 | DE |
10120942 | Oct 2001 | DE |
10043396 | Jun 2002 | DE |
0194192 | Sep 1986 | EP |
0248544 | Dec 1987 | EP |
0263360 | Apr 1988 | EP |
0276890 | Aug 1988 | EP |
0372969 | Jun 1990 | EP |
0531742 | Mar 1993 | EP |
0544485 | Jun 1993 | EP |
0552576 | Jul 1993 | EP |
0611561 | Aug 1994 | EP |
0614650 | Sep 1994 | EP |
0621014 | Oct 1994 | EP |
0625891 | Nov 1994 | EP |
0637452 | Feb 1995 | EP |
0664132 | Jul 1995 | EP |
0705878 | Apr 1996 | EP |
0719527 | Jul 1996 | EP |
0774240 | May 1997 | EP |
0797962 | Oct 1997 | EP |
0800791 | Oct 1997 | EP |
0827724 | Mar 1998 | EP |
0836838 | Apr 1998 | EP |
0847727 | Jun 1998 | EP |
0876808 | Nov 1998 | EP |
0895762 | Feb 1999 | EP |
0898944 | Mar 1999 | EP |
1017415 | Jul 2000 | EP |
1036545 | Sep 2000 | EP |
1052319 | Nov 2000 | EP |
1055757 | Nov 2000 | EP |
1090590 | Apr 2001 | EP |
1216717 | Jun 2002 | EP |
1216718 | Jun 2002 | EP |
0693523 | Nov 2002 | EP |
1273312 | Jan 2003 | EP |
1315468 | Jun 2003 | EP |
1382728 | Jan 2004 | EP |
1484070 | Dec 2004 | EP |
1561480 | Aug 2005 | EP |
1645232 | Apr 2006 | EP |
1674048 | Jun 2006 | EP |
1691606 | Aug 2006 | EP |
1782848 | May 2007 | EP |
2229918 | Sep 2010 | EP |
2792351 | Oct 2014 | EP |
2244853 | Apr 1975 | FR |
2257262 | Aug 1975 | FR |
2308349 | Nov 1976 | FR |
2453231 | Oct 1980 | FR |
2612392 | Sep 1988 | FR |
2715309 | Jul 1995 | FR |
2715405 | Jul 1995 | FR |
2724563 | Mar 1996 | FR |
2730406 | Aug 1996 | FR |
2744906 | Aug 1997 | FR |
2766698 | Feb 1999 | FR |
2771622 | Jun 1999 | FR |
2773057 | Jul 1999 | FR |
2774277 | Aug 1999 | FR |
2779937 | Dec 1999 | FR |
2859624 | Dec 2005 | FR |
2876020 | Apr 2006 | FR |
2863277 | Jun 2006 | FR |
2884706 | Apr 2008 | FR |
2929834 | Oct 2009 | FR |
2953709 | Jun 2011 | FR |
1174814 | Dec 1969 | GB |
2051153 | Jan 1981 | GB |
2306110 | Apr 1997 | GB |
H0332677 | Mar 1991 | JP |
H05237128 | Sep 1993 | JP |
H09137380 | May 1997 | JP |
H11146888 | Jun 1999 | JP |
2008538300 | Oct 2008 | JP |
2011078767 | Apr 2011 | JP |
2013535244 | Sep 2013 | JP |
2014514037 | Jun 2014 | JP |
8902445 | Mar 1989 | WO |
8908467 | Sep 1989 | WO |
9012551 | Nov 1990 | WO |
9206639 | Apr 1992 | WO |
9220349 | Nov 1992 | WO |
9310731 | Jun 1993 | WO |
9311805 | Jun 1993 | WO |
9318174 | Sep 1993 | WO |
9417747 | Aug 1994 | WO |
9507666 | Mar 1995 | WO |
9518638 | Jul 1995 | WO |
9532687 | Dec 1995 | WO |
9603091 | Feb 1996 | WO |
9608277 | Mar 1996 | WO |
9609795 | Apr 1996 | WO |
9614805 | May 1996 | WO |
9641588 | Dec 1996 | WO |
9735533 | Oct 1997 | WO |
9835632 | Aug 1998 | WO |
9849967 | Nov 1998 | WO |
9905990 | Feb 1999 | WO |
9906079 | Feb 1999 | WO |
9906080 | Feb 1999 | WO |
9951163 | Oct 1999 | WO |
0016821 | Mar 2000 | WO |
0067663 | Nov 2000 | WO |
0115625 | Mar 2001 | WO |
0180773 | Nov 2001 | WO |
0181667 | Nov 2001 | WO |
0207648 | Jan 2002 | WO |
0217853 | Mar 2002 | WO |
02078568 | Oct 2002 | WO |
03002168 | Jan 2003 | WO |
2004004600 | Jan 2004 | WO |
2004071349 | Aug 2004 | WO |
2004078120 | Sep 2004 | WO |
2004103212 | Dec 2004 | WO |
2005011280 | Feb 2005 | WO |
2005013863 | Feb 2005 | WO |
2005018698 | Mar 2005 | WO |
2005048708 | Jun 2005 | WO |
2005105172 | Nov 2005 | WO |
2006018552 | Feb 2006 | WO |
2006023444 | Mar 2006 | WO |
2006032812 | Mar 2006 | WO |
2009071998 | Jun 2009 | WO |
2009031035 | Jan 2010 | WO |
2010043978 | Apr 2010 | WO |
2010088699 | Aug 2010 | WO |
2007048099 | Sep 2010 | WO |
2011007062 | Jan 2011 | WO |
2011026987 | Mar 2011 | WO |
2011038740 | Apr 2011 | WO |
2012007578 | Jan 2012 | WO |
2012123582 | Sep 2012 | WO |
Entry |
---|
Notification of the First Office Action issued in Chinese Patent Application No. 201610439577.1 dated May 20, 2020, 19 pages; with Eng. translation. |
Amid, P., “Lichtenstein tension-free hernioplasty Its inception, evolution, and principles,” Hernia, 2004; pp. 1-7, 8, published online Sep. 2003. |
Blondin, C. et al., “Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) from Brown Seaweed,” Molecular Immuol., Mar. 1994, pp. 247-253, 31(4). |
Blondin, C. et al., “Relationships between chemical characteristics and anticomplementary activity of fucans,” Biomaterials, Mar. 1996, pp. 597-603, 17(6). |
Boisson-Vidal, C. et al., “Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan From Marine Algae,” Cardiovascular & Hematological Agents in Medicinal Chem., Jan. 2007, pp. 67-77, 5(1). |
Bracco, P. et al., “Comparison of polypropylene and polyethylene terephthalate (Dacron) meshes for abdominal wall hernia repair: A chemical and morphological study,” Hernia, 2005, pp. 51-55, 9 (1), published online Sep. 2004. |
Chen, G. et al., “A Hybrid Network of Synthetic Polymer Mesh and Collagen Sponge,” The Royal Society of Chemistry 2000, Chem. Commun., Jul. 2000, pp. 1505-1506. |
Collins, R. et al., “Use of collagen film as a dural substitute: Preliminary animal studies,” Journal of Biomedical Materials Research, Feb. 1991, pp. 267-276, vol. 25. |
Dr. S. Raz, “The Karl Mayer Guide to Tehnical Textiles,” Jan. 2000, pp. 1-36, Obertshausen, Germany. |
European Search Report for EP 15 30 5947 date of completion is Nov. 25, 2015 (4 pages). |
Examination report No. 1 for standard patent application issued in Australian Patent Application No. 2016203147 dated Feb. 13, 2020, 4 pages. |
Haneji, K. et al., “Fucoidan extracted from Cladosiphon Okamuranus Tokida Induces Apoptosis of Human T-cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells,” Nutrition and Cancer, 2005, pp. 189-201, 52(2), published online Nov. 2009. |
Haroun-Bouhedja, F. et al., “In Vitro Effects of Fucans on MDA-MB231 Tumor Cell Adhesion and Invasion,” Anticancer Res., Jul.-Aug. 2002, pp. 2285-2292, 22(4). |
Haroun-Bouhedja, F. et al., “Relationship between sulfate groups and biological activities of fucans,” Thrombosis Res., Dec. 2000, pp. 453-459, 100(5). |
Hirano, S. et al., “The blood biocompatibility of chitosan and N-acylchitosans,” J. Biomed. Mater. Res., Apr. 1985, 413-417, 19. |
Junge, K. et al., “Functional and Morphologic Properties of a Modified Mesh for Inguinal Hernia Repair,” World J. Surg., Sep. 2002, pp. 1472-1480, 26. |
Kanabar, V. et al., “Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle,” Br. J. Pharmacol., Oct. 2005, pp. 370-777, 146(3). |
Klinge, U. et al., “Foreign Body Reaction to Meshes Used for the Repair of Abdominal Wall Hernias,” Eur J. Surg, Sep. 1999, pp. 665-673, 165. |
Klinge, U. et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair,” J. Biomed. Mater. Res., Jan. 2002, pp. 129-136, 63. |
Langenbech, M. R. et al., “Comparison of biomaterials in the early postoperative period,” Surg Endosc., May 2003, pp. 1105-1109, 17 (7). |
Logeart, D. et al., “Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect,” Eur. J. Cell. Biol., Dec. 1997, pp. 385-390, 74(4). |
Malette, W. G. et al., “Chitosan, a New Hemostatic,” Ann Th. Surg., Jul. 1983, pp. 55-58, 36. |
Mühl, T. et al., “New Objective Measurement to Characterize the Porosity of Textile Implants,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, May 2007, pp. 176-183. |
Muzzarelli, R. et al., “Reconstruction of parodontal tissue with chitosan,” Biomaterials, Nov. 1989, pp. 598-604, 10. |
Notice of Reasons for Rejection issued in Japanese Patent Application No. 2016-108408 dated Feb. 17, 2020, with English translations, 8 pages. |
O'Dwyer, P. et al., “Randomized clinical trial assessing impact of a lightweight or heavyweight mesh on chronic pain after inguinal hernia repair,” Br. J. Surg., Feb. 2005, pp. 166-170, 92(2). |
Prokop, A. et al., “Water Soluble Polymers for Immunoisolation I: Complex Coacevation and Cytotoxicity,” Advances in Polymer Science, Jul. 1998, pp. 1-51, 136. |
Rao, B. et al., “Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential,” J. Biomed. Mater. Res., Jan. 1997, pp. 21-28, 34. |
Rosen, M. et al., “Laparoscopic component separation in the single-stage treatment of infected abdominal wall prosthetic removal,” Hernia, 2007, pp. 435-440, 11, published online Jul. 2007. |
Scheidbach, H. et al., “In vivo studies comparing the biocompatibility of various polypropylene meshes and their handling properties during endoscopic total extraperitoneal (TEP) patchplasty: An experimental study in pigs,” Surg. Endosc., Feb. 2004, pp. 211-220,18(2). |
Strand, S. et al., “Screening of Chitosans and Conditions for Bacterial Flocculation,” Biomacromolecules, Mar. 2001, 126-133, 2. |
Varum, K. et al., “In vitro degradation rates of partially N-acetylated chitosans in human serum,” Carbohydrate Research, Mar. 1997, pp. 99-101, 299. |
Welty, G. et al., “Functional impairment and complaints following incisional hernia repair with different polypropylene meshes,” Hernia, Aug. 2001; pp. 142-147, 5. |
Zvyagintseva,, T. et al., “Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds,” Comparative Biochem and Physiol, Jul. 2000, pp. 209-215,126(3). |
Decision of Rejection issued in Chinese Application No. 201610439577.1 dated Jan. 28, 2021, with English Translation. |
Number | Date | Country | |
---|---|---|---|
20200246124 A1 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15169829 | Jun 2016 | US |
Child | 16839095 | US |